Rosetta Genomics' Q2 Revenues Rise on Test Sales

The firm said that the number of its tests performed were up 170 percent sequentially in the quarter.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories